peptide
Tesamorelin tracker
Educational reference for Tesamorelin. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
0.6 h
Tmax
0.25 h
Category
peptide
Also known as: Egrifta, TH9507
Tesamorelin is an FDA-approved GHRH analog (Egrifta) used to reduce visceral fat in HIV-associated lipodystrophy. Subcutaneous injection.
Mechanism
A stabilized GHRH analog that stimulates the GHRH receptor to promote growth-hormone release. It is the most clinically developed GHRH analog in this catalog.
Research summary
FDA-approved (as Egrifta) to reduce excess abdominal fat in people with HIV-associated lipodystrophy, based on clinical trials. Research has also explored other metabolic contexts. Use outside the approved indication is not supported by that approval.
Reported side effects
Reported effects include injection-site reactions, joint pain, and fluid retention. Prescribing information notes considerations such as effects on glucose tolerance and IGF-1 monitoring, and contraindications. This is not a complete safety profile.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Egrifta prescribing information · FDA prescribing informationHalf-life about 26 min IV and about 38 min subcutaneous.
A TrackPep egy naplózó alkalmazás. Azt rögzíti, amit megadsz, és soha nem javasol vagy számít ki mennyiségeket.